Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
|
Acer Therapeutics Inc. (ACER)
|
Add to portfolio |
|
|
|
| Price: |
$2.40
| | Metrics |
| OS: |
24.5
|
M
| |
|
|
| Market cap: |
$58.7
|
M
| |
|
|
|
Net debt:
|
$11.5
|
M
| |
|
|
|
EV:
|
$70.2
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($48.7)
|
M
| |
|
|
| EPS |
($1.10)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 0.0 | 11.9 | 1.3 | 1.3 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | -100.0% | 846.4% | | | | | | |
| Cost of goods sold | 0.0 | 24.6 | 0.0 | 17.2 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | -12.7 | 1.3 | -15.9 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | | -106.4% | 100.0% | -1265.7% | | | | |
| Selling, general and administrative | 24.6 | 0.0 | 17.2 | 0.0 | | | | |
| Research and development | | | | | 11.8 | 13.9 | 12.5 | 8.7 |
| General and administrative | | 0.0 | | 0.0 | 11.0 | 16.0 | 9.3 | 5.2 |
| EBIT | -27.9 | -24.6 | -14.8 | -15.9 | -22.8 | -29.9 | -21.7 | -13.9 |
| EBIT margin | | -206.4% | -1174.6% | -1265.7% | | | | |
| Pre-tax income | -26.2 | -26.2 | -15.4 | -15.4 | -22.9 | -29.4 | -21.3 | -14.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -26.2 | -26.2 | -15.4 | -15.4 | -22.9 | -29.4 | -21.3 | -14.2 |
| Net margin | | -220.0% | -1220.2% | -1220.2% | | | | |
| |
| Diluted EPS | ($1.66) | ($1.66) | ($1.08) | ($1.08) | ($2.06) | ($2.91) | ($2.49) | ($3.84) |
| Shares outstanding (diluted) | 15.8 | 15.8 | 14.3 | 14.3 | 11.1 | 10.1 | 8.6 | 3.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|